Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Across Novo Nordisk, our people wake up every day knowing their work matters.
From the researcher analysing data, to the manufacturing specialist ensuring quality in every single dose, to the sales professional making sure our treatments reach the people who need them – our people share something powerful: the collective belief that science and innovation can truly transform lives.
It’s not always easy. Breakthroughs take years. Setbacks happen. But knowing that your work could bring hope to millions living with serious chronic diseases. That’s what keeps us going - driving lasting change for long-term health.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.
The Hemophilia Federation of America and the National Hemophilia Foundation announced that they had been contacted by Genentech, a Roche company, about the deaths of five patients receiving Hemlibra (emicizumab-kxwh) for hemophilia A.
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug oral semaglutide.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Will this new buy be enough for Celgene investors?
The offers underline Novo Nordisk’s interest in expanding beyond diabetes and into the rare diseases market.
reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.
JOBS
IN THE PRESS